The Company has established a multi-channel research and development infrastructure composed of in-house R&D and collaborations with well-known institutions and scientists. There are 50 in-house researchers and engineers working in the following functions, either independently or in collaboration with external institutions:
Comprehensive testing
New product development
Nutraceutical and healthy food development
Standard extracts development
Biopharmaceutical products development
Mid-scale testing
Diagnostic reagent development
Product approval submission
To become an innovative enterprise, Renhuang continually employs young talent to strengthen its research team. Currently the Company’s open and innovative R&D environment consisting of Proprietary R&D Centers, Cooperation R&D Centers and Post-doctoral Workstations.
Proprietary R&D Centers – These centers are responsible for initial research of potential products and development of existing product upgrades.
Cooperation R&D Centers – These centers have established committees consisting of well-know medical professionals in China, who specialize in biopharmaceutical and botanical medicines. The committee guides and advises the execution and direction of R&D projects, as well as evaluates research findings.
Post-doctoral Workstations – The Company’s post-doctoral research workstation approved and supported by the Chinese government. The center allows post-doctoral fellows to work on projects related to Renhuang’s products and technology development.
R&D Achievements - Renhuang has received the following recognition for its research and development:
Siberian Ginseng (Acanthopanax) Development Project
2009 The Siberian Ginseng (Acanthopanax)
Polysaccharides products were awarded “Key Products in
Heilongjiang Province” by Heilongjiang Science and
Technology Office
The “Pollution-Free and Environment-Friendly Extraction Process for Total Alkaloids of Sophora Flavescens and
Colorless Sterile Injection against Hepatitis B” project was listed as a Major Intellectual Property Rights Project by Harbin Intellectual Property Bureau.
The “Industrialization of Siberian Ginseng (Acanthopanax) Extraction: Total Glucosides, Total Flavonoids and Polysaccharides” project was listed a special high-tech project by Heilongjiang Development and Reform Commission.
The “Siberian Ginseng (Acanthopanax) Oral liquid” project
was listed as a new industrialization special project by
Harbin Development and Reform Commission
2008 The “Research on New Siberian Ginseng (Acanthopanax)
Anti-depression Drugs” project was listed as a Harbin technological
innovation talents project by Harbin Science and Technology Bureau
2007 The “Secondary Development and Industrialization of Genuine Medical
Materials Siberian Ginseng (Acanthopanax) Series Products” project
was listed as a major provincial-level pre-project by Heilongjiang
Development and Reform Commission
Renhuang has been successful in separating effective components of Siberian Ginseng (Acanthopanax), namely total glucosides, total flavonoids and syringin, in particular, syringin has significant effects in the treatment of depression and nerve regulation. The Company‘s most promising product candidates, currently in the pilot testing stage.
Schisandra (wild plant) Integrated Development Project
Schisandra is a wild plant with high medical and health values. Modern studies have shown that Schisandra contains lignin, which has strong effects in treating insomnia. At present, the Company has completed research on method of measuring total content of lignin and setting quality standards, laying the foundation for advanced development of Schisandra products.
Total Alkaloids of Sophora Flavescens Development Project
This new drug is a potential Hepatitis B therapy, total alkaloids of Sophora flavescens can be used to replace α - interferon, matrine and oxymatrine injections.
Comprehensive testing